Programmed death ligand-1 expression in non-small cell lung cancer

Detterbeck, 2009, The new lung cancer staging system, Chest, 136, 260, 10.1378/chest.08-0978 Petrelli, 2009, Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology, J Clin Oncol, 27, 6052, 10.1200/JCO.2009.26.6171 Chen, 2004, Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity, Nat Rev Immunol, 4, 336, 10.1038/nri1349 Sznol, 2013, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer, Clin Cancer Res, 19, 1021, 10.1158/1078-0432.CCR-12-2063 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, New Eng J Med, 366, 2455, 10.1056/NEJMoa1200694 Mu, 2011, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med Oncol, 28, 682, 10.1007/s12032-010-9515-2 Konishi, 2004, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin Cancer Res, 10, 5094, 10.1158/1078-0432.CCR-04-0428 Chen, 2012, Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study, Tumori, 98, 751, 10.1177/030089161209800612 Boland, 2013, Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung, Clin Lung Cancer, 14, 157, 10.1016/j.cllc.2012.05.006 Anagnostou, 2009, Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma, J Clin Oncol, 27, 271, 10.1200/JCO.2008.17.0043 Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730 Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra37, 10.1126/scitranslmed.3003689 McCabe, 2005, Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis, J Natl Cancer Inst, 97, 1808, 10.1093/jnci/dji427 Bordeaux, 2012, Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen, PLoS ONE, 7, e36559, 10.1371/journal.pone.0036559 Camp, 2002, Automated subcellular localization and quantification of protein expression in tissue microarrays, Nat Med, 8, 1323, 10.1038/nm791 Klintrup, 2005, Inflammation and prognosis in colorectal cancer, Eur J Cancer, 41, 2645, 10.1016/j.ejca.2005.07.017 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, New Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Hamanishi, 2007, Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer, Proc Natl Acadl Sci USA, 104, 3360, 10.1073/pnas.0611533104 Mu, 2011, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med Oncol, 28, 682, 10.1007/s12032-010-9515-2 Nomi, 2007, Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, 13, 2151, 10.1158/1078-0432.CCR-06-2746 Thompson, 2006, Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res, 66, 3381, 10.1158/0008-5472.CAN-05-4303 Lipson, 2013, PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival, Cancer Immunol Res, 1, 54, 10.1158/2326-6066.CIR-13-0034 Droeser, 2013, Clinical impact of programmed cell death ligand 1 expression in colorectal cancer, Eur J Cancer, S0959-8049, 00123 Spranger, 2013, Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells, Sci Transl Med, 5, 200ra116, 10.1126/scitranslmed.3006504